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Prodynorphin peptide immunocytoehemistrv in rhesus monkey brain. PEPTIDES 6: Suppl. 2, 155-166, 1985. --The 
present study describes the immunocytochemical distribution of peptides derived from the prodynorphin precursor in the 
brain of the rhesus monkey (Macaea mulatta). Animals were treated with colchicine (intracerebroventricularly) prior to 
perfusion to enhance the observation of perikaryal immunoreactivity. Using antisera generated against dynorphin A(1-17), 
dynorphin B(1-13), and prodynorphin(186-208) (or bridge peptide), the anatomical distribution of dynorphin systems was 
mapped. The results indicate a widespread neuronal localization ofimmunoreactivity from the cerebral cortex to the caudal 
medulla. Anti-dynorphin B and anti-bridge peptide sera proved useful for the demonstration of neuronal perikarya, while 
the dynorphin A antiserum was best for localizing terminal projection fields. Immunoreactive perikarya are located in 
numerous brain loci, including the cingulate cortex, caudate nucleus, amygdala, hypothalamus (especially the magnocellu- 
lar nuclei), thalamus, substantia grisea centralis, parabrachial nucleus, nucleus tractus solitarius, and other nuclei. In 
addition, fiber and terminal immunoreactivity are seen in varying densities in the striatum and pallidum, substantia 
innominata, hypothalamus, substantia nigra pars reticulata, parabrachial nucleus, spinal trigeminal nucleus, and other 
areas. The distribution of prodynorphin peptides in the brain of the monkey is similar to that described for the rat brain; 
however, significant differences also exist. Other interspecies differences in the anatomy of prodynorphin and 
proenkephalin neuronal systems in the monkey and human brain are further discussed. 
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PEPTIDES derived from the prodynorphin precursor [23] 
include dynorphin A, dynorphin B (or rimorphin), and 
a-neo-endorphin [11, 13, 15, 24, 31, 48]. The initial im- 
munocytochemical  observations of dynorphin distribution in 
the central nervous system demonstrated the coexistence of 
dynorphin A(I-13) and arginine-vasopressin in the mag- 
nocellular neurons of the supraoptic and paraventi ' icular nu- 
clei as well as in nerve terminals in the neural lobe of the 
pituitary [57,58]. Similar observations were also made using 
antisera generated against a-neo-endorphin [61,65, 66]. Sub- 
sequently, we and other investigators were able to show 
dynorphin A, dynorphin B, and a-neo-endorphin to be co- 
localized in neuronal perikarya in several regions of the fore- 
brain and brain stem [62,63], confirming the biochemical and 
molecular biological studies of the prodynorphin precursor 
[231. 
Most previous immunocytochemical  [28, 30, 34, 35, 44, 
51, 57-63, 65-67] and radioimmunoassay [2, 4, 5, 8, 12, 14, 
22, 37, 39, 40, 41,64, 6%73] studies of dynorphin distribution 
in the central nervous system have focused on its localiza- 
tion in the brain and spinal cord of rat. However ,  our knowl- 
edge of dynorphin anatomy in the primate brain is incom- 
plete and has been limited to anatomical studies of opioid 
peptides in the human and monkey basal ganglia [20,21] and 
opioid peptide-receptor  relationships in rhesus monkey brain 
[32,33], as well as radioimmunoassay studies of  human and 
monkey central nervous system [7, 16, 38, 42, 43, 49]. On the 
other hand, the enkephalins have been shown to be distrib- 
uted widely in neuronal perikarya and fibers throughout the 
central nervous system of  the African green monkey [ 17,18]. 
We have also recently described the distribution of 
/3-endorphin and other peptides derived from pro- 
opiomelanocortin in the brain of the rhesus monkey [26]. 
In these latter studies of the distribution of enkephalins and 
/3-endorphin in monkey brain, striking similarities have been 
noted with their distribution in rat brain [27, 29, 35]. How- 
ever, some notable differences have also been observed 
[17,26]. Because of interspecies variation in the distribution 
of opioid peptides, as shown for other neuropeptides [9] as 
well as classical neurotransmitters [46], we have chosen to 
further investigate the immunocytochemical  distribution of 
peptides derived from prodynorphin in the brain of the 
rhesus monkey and compare the present findings with those 
reported for the rat brain. Preliminary results from this study 
have been presented elsewhere [25]. 
METHOD 
Brains from either normal (n= l) or colchicine-pretreated 
(n=5) adult rhesus monkeys (Macaca mulatta, housed indi- 
vidually at the University primate colony) were processed 
for peroxidase-antiperoxidase (PAP) immunocytochemistry.  
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Each animal was anesthetized by injection of sodium pen- 
tobarbital (30 mg/kg) into the saphenous vein at 9 a.m. The 
animal was then transferred onto a surgical table and artifi- 
cially respirated via an endotracheal tube. The rib cage was 
removed, and the pericardium excised. The left ventricular 
wall was slit open and a plastic cannula was inserted through 
the cavity of the left ventricle into the aorta and tied firmly in 
place with suture. The right atrium was punctured to allow 
for an open circulation, and then the cardiovascular  system 
was flushed with two liters of normal saline through the aor- 
tic cannula. Immediately following this step, the animal was 
trans-aortically perfused with 16 liters of neutral-buffered 4% 
formaldehyde for approximately 30 minutes. The cannula 
was removed,  the head was severed from the trunk, and the 
brain was removed and either cut stereotaxically in frontal or 
parasagittal planes, or postfixed intact for 24 hours in the 
same fixative. The tissue that was stereotaxically cut into 1 
cm thick slices was further postfixed for 2-4 hours. These 
slices were then transferred into 15% sucrose in 0.02 M 
phosphate-buffered saline (PBS) and stored for 24 hours at 
4°C. The tissue was frozen in -50°C isopentane or liquid 
nitrogen, and stored at -80°C. The brain that was postfixed 
intact for 24 hours was immersed into successively higher 
concentrations of sucrose (10, 20, 30%) for several days, 
each at 4°C, until the tissue was completely penetrated by 
sucrose. This brain was used for floating-section im- 
munocytoclaemistry. 
Frozen-Section lmmunocytochemistry 
The frozen brain slices were stored at -80°C, placed in 
a cryostat  set at -20°C, and sectioned at either 20 or 32 tzm 
and thaw-mounted onto subbed glass slides. The slides were 
also stored at -80°C. The sections to be processed for PAP 
immunocytochemistry [30] were allowed to air dry and incu- 
bated with normal goat serum (NGS) (GIBCO) for 10 min- 
utes at 37°C. This solution was drained and replaced by pri- 
mary rabbit antiserum raised against dynorphin A(I-17),  
dynorphin B(I-13), or porcine prodynorphin(186-208) 
(bridge peptide). All antisera were diluted in 0.02 M PBS 
containing 0.3% Triton X-100. After 1 hour incubation, the 
slides were placed in moist boxes and stored overnight at 
4°C. The next day, the sections were washed in several 
changes of PBS, incubated at 37°C with goat anti-rabbit 
serum (GAR) (Arnel) at 1:1000 dilution for 30 minutes, and 
again stored overnight at 4°C. On the third day,  the sections 
were washed in PBS and incubated with rabbit antiserum 
against horseradish peroxidase (HRP) at 1:200 dilution for 40 
minutes followed by PBS wash and subsequent incubation 
with 4/xg/ml HRP enzyme (Sigma, type VI) for 40 minutes. 
After PBS wash, the sections were reacted in a solution of 
0.125 mg/ml diaminobenzidine (Sigma) and 0.06%. hydrogen 
peroxide for 15 minutes at room temperature.  The sections 
were then rinsed in distilled water, briefly immersed into 
0.01% osmium tetroxide, dehydrated through graded 
ethanols and xylenes, and coverslipped in Permount. 
Floating-Section lmmunocytochemistry 
The brain was removed from 30% sucrose and placed on a 
sliding microtome, frozen with dry ice, and sectioned at 
35-50 /xm. The sections were stored in PBS at 4°C until 
processed for PAP immunocytochemistry [17]. Designated 
sections were transferred into marked incubation dishes and 
preincubated with 10% NGS in Triton-PBS for 20-30 min- 
utes. Subsequently, the sections were incubated with pri- 
mary rabbit antisera against dynorphin A(I-17),  dynorphin 
B(1-13), or dynorphin bridge peptide. Incubation was car- 
fled out at 4°C for approximately 72 hours with constant 
shaking. Then, the sections were washed in several changes 
of PBS and preincubated in NGS for 10 minutes followed by 
GAR (1:1000 dilution) incubation at 4°C overnight. Next,  
after several PBS washes, the sections were again preincu- 
bated in NGS for 10 minutes prior to incubation with PAP 
complex (Cappel) (1:500 dilution) for 1 hour at room tem- 
perature. Some sections were processed according to the 
procedure described in the previous section (i.e., HRP 
antibody followed by enzyme). After several PBS washes, 
the sections were rinsed in 0.05 M Tris buffer (pH 7.6) and 
incubated in Tris buffer containing 0.5 mg/ml diaminoben- 
zidine and 0.01% hydrogen peroxide for 20 minutes. This 
reaction was followed by several rinses in Tris buffer and 
then PBS, after which the sections were stored in 10% for- 
malin until mounted onto subbed glass slides. For  the latter, 
the sections were rinsed in distilled water and mounted in a 
solution of 0.5% gelatin in 40% e thane .  The slide-mounted 
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sections were allowed to air dry and thCen were briefly osml- 
cated with 0.2% osmium tetroxide, rinsed, dehydrated 
through graded ethanols, cleared in xylene, and mounted in 
Permount. Observations and photomicrographs were made 
using a Leitz microscope. The low-power photographs were 
made using a macroscope. 
Colehicine Treatment 
Several animals were pretreated with colchicine to 
enhance the observed perikaryal immunoreactivity. Since 
colchicine inhibits the synthesis of microtubules, it causes a 
retardation in axonal transport (see [47]), which results in an 
accumulation of synthesized peptides in neuronal perikarya 
and truncal axons [30]. Prior to this treatment,  each animal 
was anesthetized with sodium pentobarbital injected into the 
saphenous vein. The head was fixed onto a stereotaxic appa- 
ratus, the skull exposed,  and a hole drilled into the skull 8.0 
mm anterior to bregma and 4.0 mm lateral to midline. Col- 
chicine (75-600/xg/kg body weight) dissolved in 0.9% saline 
was drawn into a calibrated plastic tube attached to a can- 
nula which was inserted through the hole directly into the 
right lateral cerebral ventricle (19.6 mm deep). The col- 
chicine solution (0.5 ml) was allowed to diffuse into the cere- 
brospinal fluid by gravity flow. The cannula was removed 
and the hole was filled with bone wax and the scalp sutured. 
In order to decrease the probability of seizures and maintain 
the comfort of  the animal, each monkey was kept under 
sedation with intramuscular injections of valium (5 mg/ml) 
for 24 to 48 hours prior to perfusion as described above. 
RESULTS 
The antisera raised against dynorphin A(I-17) and dynor- 
phin B(1-13) have been previously characterized [30, 59--62]. 
The anti-prodynorphin(186-208) or bridge peptide antiserum 
has also been extensively characterized in our laboratory. 
Under immunocytochemical  conditions, each antibody used 
is highly specific for the peptide antigen against which it was 
raised, and can be blocked by 1 /zM concentration of that 
peptide. They could not, however,  be blocked by other pep- 
tides tested in up to 50 tzM concentrations,  including those 
which have amino acid sequences in common with the pep- 
tide antigen• For  example, the immunoreactivity seen with the 
dynorphin A(1-17) antiserum could be blocked by dynorphin 
A(I-17)  and dynorphin A(1-8), but not by dynorphin 
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FIG. 1. Dynorphin B immunoreactive perikarya in the anterior cingulate cortex (subcallosal gyrus [33]). These small neurons 
are found in layers II and III. The arrows in panel A point to two neurons in layer II that are shown magnified in panel B. Bar 
(A)=200 p.m. Bar (B)=50/zm. 
B(1-13), c~-neo-endorphin, bridge peptide, Leu- 
enkephalin, Met-enkephalin, BAM-22P, peptide E, 
proenkephalin(192-203), or fl-endorphin. Likewise, the 
immunoreactivity observed using the dynorphin B(1-13) 
antiserum was blockable by dynorphin B(1-13), but not 
by dynorphin A(1-17), dynorphin A(1-8), c~-neo- 
endorphin, bridge peptide, Leu-enkephalin, Met-enkepha- 
lin, BAM-22P, peptide E, proenkephalin(192-203), or 
fl-endorphin. The bridge peptide immunoreactivity also 
proved to be specific since it was blocked by bridge peptide, 
i.e., prodynorphin(186-208), but not by dynorphin A(I-17), 
dynorphin B(1-13), a-neo-endorphin, Leu-enkephalin, 
Met-enkephalin, proenkephalin(192-203), or fl-endorphin. 
Although some fiber and terminal-like immunoreactivity 
could be seen in normal, untreated animals, the best results 
were obtained using animals pretreated with varying doses of 
colchicine. Increasingly intense perikaryal staining was 
noted with successively higher doses of colchicine in the 
cryostat-sectioned, slide-mounted tissue processed for PAP 
immunocytochemistry. The best results for both perikarya 
and fibers, however, were obtained using the technique of 
floating-section PAP immunocytochemistry. In these tis- 
sues, intense immunoreactivity could be seen in neuronal 
perikarya, fibers, and terminals in an animal that was given 2 
mg colchicine, intracerebroventricularly. The best perik- 
aryal immunostaining was observed with the dynorphin B 
(Figs. 1,3B and C, 6) and bridge peptide (Figs. 2, 3A, 4B and C) 
antisera, with more intense fiber staining seen using the 
dynorphin A antiserum (Figs. 2, 4A, 5). 
Neuronal perikarya immunoreactive tbr prodynorphin 
peptides are found in numerous brain areas (see Fig. 8 for a 
summary). With the exception of  the magnocellular sup- 
raoptic and paraventricular nuclei (Fig. 3), and some lateral 
hypothalamic area neurons (Fig. 4B), most dynorphin 
neurons are small and scattered within each nucleus or re- 
gion (e.g., Fig. 4C). The supraoptic nucleus is densely 
packed with dynorphin-positive perikarya throughout its 
rostral-caudal extent (Fig. 3A and B), in parts both lateral 
and medial to the optic tract. In the paraventricular nucleus, 
immunoreactive perikarya are seen loosely organized adja- 
cent to the third ventricle both dorsally and ventrally (Fig. 
3A and C). Other hypothalamic areas that contain scattered 
immunoreactive perikarya include the infundibular, ven- 
tromedial, dorsomedial, and medial mammillary nuclei, as 
well as the lateral hypothalamic area (see Fig. 8). Numerous 
immunoreactive perikarya are also seen in the medial preopo 
tic area, some occupying a periventricular position. 
Elsewhere in the diencephalon, scattered immunoreactive 
perikarya are seen only in the reuniens nucleus of thalamus 
(Fig. 8). 
Numerous, small, dynorphin-positive interneurons are 
seen in the anterior cingulate cortex (subcallosal gyrus), 
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FIG. 2. This frontal view of a section through the telencephalon shows the distribution of 
dynorphin A immunoreactivity in the basal ganglia. Note the intense staining in the ventral 
pallidum. The star indicates the ventromedial region of the head of caudate nucleus where 
numerous dynorphin neurons were seen. A few of these neurons (arrows), immunoreac- 
tive for bridge peptide, can be seen in the inset. Bar=4 mm. Bar (inset)=50 tzm. ac: 
anterior commissure, bst: bed nucleus of stria terminalis, cau: caudate, cc: corpus cal- 
losum, ci: internal capsule, fx: fornix, gp: globus pallidus, Iv: lateral ventricle, put: puta- 
men, vp: ventral patlidum. 
mainly in layers II and III (Fig. 1). In the striatal complex, 
dynorphin immunoreactive perikarya are seen in the ven- 
tromedial aspect of the head of caudate nucleus, adjacent to 
the lateral ventricle (Fig. 2). No immunoreactive perikarya 
could be detected in the putamen. Other telencephalic nuclei 
which contain scattered perikarya include the nucleus ac- 
cumbens, bed nucleus of stria terminalis, and the central 
nucleus of amygdala (Fig. 8). In the latter, perikarya are very 
sparse; only occasional dynorphin-positive neurons are seen 
in a single section (Fig. 4C). 
In brain stem, scattered dynorphin-containing perikarya 
can be seen in mesencephalic substantia grisea centralis 
(periaqueductal gray) (Fig. 8). Elsewhere, the dorsal para- 
brachial nucleus (Fig. 6), nucleus tractus solitarius, and lateral 
reticular nucleus all exhibit scattered dynorphin-positive 
neurons. Scattered perikarya are also seen in the vicinity of 
the locus coeruleus and the mesencephalic trigeminal nu- 
cleus, but not within either nucleus. Other positive perikarya 
are present in ventrolateral pontine reticular formation, at 
the level of the motor facial nucleus. In the caudal medulla, 
numerous dynorphin-positive perikarya are situated in the 
marginal zone as well as deeper layers of  the spinal trigemi- 
hal nucleus (Fig. 7). 
Several areas of the brain contain dynorphin-positive fi- 
bers and terminals (see Fig. 8 for a summary). Scattered 
fibers are seen as rostrally as the anterior cingulate cortex 
(Fig. 1). In the striatum, scattered fiber immunoreactivity 
can be seen in the caudate and putamen, the latter exhibiting 
only light immunoreactivity (Figs. 2, 4A). Dense woolly fiber 
immunoreactivity, as described before [19], is seen in both 


















FIG. 3. Panel A shows a frontal section through the hypothalamus and basal ganglia, immunoreactive for dynorphin bridge 
peptide. Note the intense staining in the internal globus pallidus and perikaryal staining in the magnocellular neurons. In 
panels B and C, dynorphin B immunoreactive magnocellular neurons are shown in the supraoptic (A) and paraventricular (B) 
nuclei. Bar (A)=2 mm. Bars (B,C)= 100 /xm. 3v: third ventricle, aha: anterior hypothalamic area, gpe: external globus 
pallidus, gpi: internal globus pallidus, lha: lateral hypothalamic area, oc: optic chiasm, pvn: paraventricular nucleus, son: 
supraoptic nucleus. 
the external and internal globus pallidus (Figs. 2, 3A, 4A). 
This dense immunostaining also extends into the ventral pal- 
lidum (Fig. 2). By contrast, in the olfactory area, only light 
immunoreactivity is seen in the region of the islands of Cal- 
leja. In most of the other telencephalic and diencephalic re- 
gions which contain immunoreactive perikarya (see above), 
varying densities of dynorphin positive fibers are also seen. 
Of particular interest, immunoreactive varicosities are 
numerous in the supraoptic and paraventricular nuclei (Fig. 
3B and C), as well as the lateral hypothalamic area (Fig. 4B). 
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FIG. 4. Panel A is a frontal section demonstrating dynorphin A immunoreactivity in the basal ganglia, hypothalamus, and 
amygdala. Note the intense immunoreactivity in the medial region of the internal globus pallidus (star). This region is 
magnified in the inset to show woolly fiber immunoreactivity (arrowheads). Note also the immunoreactivity in the central 
nucleus of amygdala. In panels B and C, bridge peptide immunoreactivity can be seen in neuronal perikarya (arrows) and 
processes in the lateral hypothalamic area (B) and the central nucleus of amygdala (C). Bar (A)=4 mm. Bar (A, inset)=50 
/xm. Bars (B,C)=50 /xm. 3v: third ventricle, ace: central nucleus of amygdala, am: medial nucleus of amygdala, cau: 
caudate, ci: internal capsule, din: dorsomedial nucleus, gpe: external globus pallidus, gpi: internal globus pallidus, Iha: 
lateral hypothalamic area, ot: optic tract, put: putamen, vm: ventromedial nucleus. 
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FIG. 5. Dynorphin A immunoreactivity in the substantia nigra pars reticulata, seen in a frontal section through the midbrain (panel A). Note 
that this immunoreactivity is densest in the more medial aspects of the substantia nigra (star), and appears in the form of long woolly fibers 
(arrows) and patches, magnified in panel B. Bar (A)=2 mm. Bar (B)=200/xm. llI: oculomotor nerve, aq: cerebral aqueduct, cp: cerebral 
peduncle, rn: red nucleus, sgc: substantia grisea centralis, snc: substantia nigra pars compacta, snr: substantia nigra pars reticulata, vta: 
ventral tegmental area. 
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FIG. 6. Panel A shows dynorphin B immunoreactive perikarya in the parabrachial nucleus, in a frontal plane through the rostral pons. A 
region of the parabrachial nucleus is magnified in panel B to demonstrate two immunoreactive neurons (arrows). Bar (A)= 200/zm. Bar (B)= 50 
p.m. bc: brachium conjunctivum. 
162 KHACHATURIAN ET AL.  
A 
/ ? ! / i / ~  iii ~!~ ~ . . . . .  : ~!'i~:~ ' ii' !~iii!~!' ~ . . . .  ~i!~ 
/ / / ! i/i! ̧ ¸Liiii~ii~/ii ~ i  ~ i  
i i  ̧  ?,; ~ i ~  
FIG. 7. Dynorphin B immunoreactivity is seen in a frontal section through the caudal medulla. Note the immunoreactivity in the marginal 
zone (arrowheads) of the spinal trigeminal nucleus. Two immunoreactive neurons (arrows) located in this region are seen magnified in the 
inset. The right arrow points to a neuron in the spinal trigeminal tract. Bar=400 p~m. Bar (inset)=50/zm. stt: spinal trigeminal tract. 
Fibers are also seen in the internal layer of the median emi- 
nence. In the thalamus, only light, diffuse immunoreactivity 
is seen in the anterior nuclei (see Fig. 8). 
In the brain stem, by far the densest accumulation of 
immunoreactive fibers is seen in the substantia nigra pars 
reticulata (Fig. 5). Here, as in the globus pallidus, woolly 
fiber immunoreactivity is seen throughout, but is particularly 
dense more medially (Fig. 5B). Elsewhere in the brain stem, 
scattered fibers are seen in the substantia grisea centralis, 
interpeduncular nucleus, and the inferior olivary nucleus. 
Other scattered fibers are seen in the parabrachial (Fig. 6), 
locus coeruleus, mesencephalic trigeminal, tractus sol- 
itarius, and lateral reticular nuclei. Lastly, in the spinal 
trigeminal nucleus, immunoreactive varicosities are seen in 
the marginal zone and to a lesser extent in deeper layers (Fig. 
7). 
D I S C U S S I O N  
This study investigated the distribution of dynorphin A, 
dynorphin B, and dynorphin bridge peptide or 
prodynorphin(186-208) in the brain of the adult rhesus mon- 
key, Macaca mulatta. The immunoreactivity seen using all 
three antisera appeared to be very similarly distributed in all 
areas of the brain studied. This is consistent with the 
demonstration of co-synthesis of these peptides from a single 
precursor, prodynorphin [23], as well as their colocalization 
within the same neurons in numerous brain regions [61-63, 
65, 66]. Some minor differences noted among the three 
antisera in the intensity of staining is probably due to differ- 
ences in sensitivity of these antisera, and perhaps also due to 
the differential concentrations of specific peptide antigens in 
different parts of the neuron, i.e., cell body vs. axonal pro- 
jections and terminals. Thus, the observation that dynorphin 
B and bridge peptide immunostaining is stronger in neuronal 
perikarya when compared to that observed using the dynor- 
phin A antiserum, might well be the result of differences in 
antibody sensitivity and/or the lack of abundance of dynor- 
phin A in perikarya. The latter possibility seems particularly 
plausible since this antiserum (i.e., anti-dynorphin A) stains 
terminal innervation fields much more strongly, which might 
be due to a relatively higher content of dynorphin A in 
neuronal terminals. This interpretation is further supported 
by the biochemical observations of the relative abundance of 
dynorphin A over dynorphin B in both the rat and monkey 
substantia nigra [7,8], a terminal field of striato-nigral pro- 
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FIG. 8. Schematic summary of prodynorphin peptide systems in the rhesus monkey brain. In this 
parasagittal view, neuronal perikarya are shown as solid triangles, while fibers and terminals are 
depicted as diagonal lines, ac: anterior commissure, acb: nucleus accumbens, ace: central nucleus of 
amygdala, at: anterior nucleus of thalamus, bst: bed nucleus of stria terminalis, cau: caudate, cbl: 
cerebellum, cc: corpus callosum, cgx: cingulate cortex, dm: dorsomedial nucleus, gp: globus pallidus, 
hpc: hlppocampus, ic: interior colliculus, inf: infundibular nucleus, lc: locus coeruleus, lha: lateral 
hypothalamic area, lrn: lateral reticular nucleus, ma: medial mammillary nucleus, nts: nucleus tractus 
solitarius, oc: optic chiasm, otu: olfactory tubercle, pv: periventricular nucleus of thalamus, pc: 
posterior commissure, put: putamen, pvn: paraventricular nucleus, poa: preoptic area, pbn: para- 
brachial nucleus, pn: pons, rf: recticular formation, re: reuniens nucleus of thalamus, sc: superior 
colliculus, snr: substantia nigra pars reticulata, sgc: substantia grisea centralis, son: supraoptic nu- 
cleus, stn: spinal trigeminal nucleus. 
jections [10, 41, 52, 72]. In fact, dynorphin A(I-17) might be 
a biosynthetic intermediate in several regions of the brain 
including substantia nigra, with dynorphin A(1-8) being a 
major end product [8, 64, 73]. However, the dynorphin A 
antiserum used in the present study equally recognizes 
dynorphin A(1-8) (see results). 
In previous studies of dynorphin immunoreactivity in the 
rat brain, a consistent finding has been the close anatomi- 
cal association between perikarya and projections of 
dynorphin-containing and enkephalin-containing neurons 
[30, 35, 60]. These observations can now be extended to the 
rhesus monkey brain as well. In fact, most areas described 
here to contain dynorphin perikarya and fibers, also contain 
enkephalin immunoreactive neurons [17,18]. However, 
enkephalin immunoreactivity appears to be more widely dis- 
tributed than that of dynorphin. For example, areas that 
have been shown to contain enkephalin but not dynorphin 
neuronal perikarya include: septal nuclei, basal and medial 
amygdaloid nuclei, lateral and intermediate mammillary nu- 
clei, periventricular nucleus of thalamus, habenular nuclei, 
inferior colliculus, interpeduncular nucleus, nucleus 
trapezoideus, nucleus of the lateral iemniscus, nuclei of the 
raphe, ventral and dorsal tegmental nuclei, and locus 
coeruleus (compare the present findings with those of [18]). 
The other brain regions (with the exception of cerebral cor- 
tex, not considered in the latter study) that contain dynor- 
phin neurons also contain enkephalin-positive perikarya. 
Furthermore, enkephalin projections also appear to be more 
widespread in the rhesus monkey brain when compared to ( 
dynorphin projections (see [17]). b 
The above observations raise the possibility of coexistence 
of prodynorphin and proenkephalin in some neurons in the 
rhesus monkey brain. For example, the existence of both 
dynorphin and enkephalin immunoreactivity in the hypotha- 
lamic supraoptic and paraventricular nuclei may suggest 
their co-synthesis within magnocellular neurons in this spe- 
cies. However, since detailed colocalization studies have not 
been carried out in the monkey magnocellular system, it is 
not clear whether either dynorphin or enkephalin or both 
exist in the vasopressin or oxytocin producing neurons (see 
[57]). Leu-enkephalin immunoreactivity has been shown to 
occur in a small subpopulation of magnocellular paraven- 
tricular neurons [6]. In addition, Haber and Elde [18] have 
reported the existence of Met-enkephalin immunoreactivity 
in both supraoptic and paraventricular nuclei. These obser- 
vations lend support for the synthesis of both prodynorphin 
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and proenkephalin in monkey magnocellular neurons, al- 
though not necessarily within the same cells. However ,  sig- 
nificant interspecies variations appear  to exist in the distri- 
bution of  proenkephalin and prodynorphin peptides in mag- 
nocellular neurons. In the cat hypothalamus, Met-en- 
kephalin immunoreactivity has been noted in some mag- 
nocellular neurons, but not colocalized with either vaso- 
pressin or oxytocin [36]. In the bovine hypothalamus, Met- 
enkephalin immunoreactivity has been associated with 
oxytocin neurons [50]. In the rat, however,  Leu- and Met- 
enkephalin immunoreactivity appear to be confined to par- 
vocellular paraventricular neurons, whereas all dynorphin 
antisera tested to date are colocalized within vasopressin 
neurons in both the supraoptic and paraventricular nucleus 
[57, 60-63]. 
Another  area of  variation in the distribution of dynorphin 
and enkephalin is seen in the basal ganglia. Considerable 
species variations have been noted in the distribution of 
these peptides in the globus pallidus of the rat, cat, monkey, 
and human [3, 20, 21]. In this structure, enkephalin and 
dynorphin immunoreactivity occur in dense plexuses of  fi- 
bers wrapped around the non-immunoreactive dendrites of 
pallidal neurons. This so-called woolly fiber morphology has 
been described more extensively elsewhere [19]. In both 
monkey and human brain, enkephalin immunoreactivity is 
densely distributed within the external globus pallidus, being 
less pronounced in the internal region [1, 20, 21]. By con- 
trast, dynorphin immunoreactivity appears equally dense in 
the medial aspect  of the monkey internal globus pallidus. 
Haber  and Watson [20] have further noted differences in the 
distribution of these two peptides in the ventral striatum, 
amygdala,  bed nucleus of stria terminalis, and substantia 
nigra of the rat, monkey, and human brain. For  example,  
unlike the rat substantia nigra pars reticulata where 
enkephalin immunoreactivity is very weak when compared 
to that of dynorphin, this structure in the monkey and human 
appears to be densely innervated by both dynorphin and 
enkephalin fibers [20]. Furthermore,  dynorphin im- 
munoreactivity in the monkey pars reticulata is denser me- 
dially, in contrast  to the more even distribution of  dynorphin 
immunoreactivity within the pars reticulata of rat substantia 
nigra [30]. 
Other similarities and differences are apparent  in the dis- 
tribution of prodynorphin peptides in the rhesus monkey and 
rat brain. Most diencephalic and brain stem nuclei that con- 
tain prodynorphin immunoreactive peptides in the rat also 
exhibit this immunoreactivity in the monkey brain. How- 
ever, in the rat brain, dynorphin immunoreactive fibers are 
further distributed in areas that are devoid of im- 
munocytochemically detectable dynorphin in the monkey. 
These include superior and inferior colliculi, main trigeminal 
sensory and motor nuclei, facial and vestibular nuclei, nuclei 
reticularis gigantocelluaris and paragigantocellularis (equiv- 
alent of primate magnocellular reticular nuclei), and nuclei 
raphe dorsalis and raphe magnus. More strikingly, in com- 
parison to rat, the monkey telencephalon is significantly de- 
ficient in dynorphin immunoreactivity.  We have been able to 
observe only a few immunoreactive per ikarya and fibers in 
the anterior cingulate cortex of the monkey, whereas large 
numbers of  dynorphin-containing neurons have been re- 
ported in the rat cerebral cortex [35]. In the monkey amyg- 
dala, only a few dynorphin-posit ive perikarya can be seen in 
the central nucleus, whereas in the rat central nucleus of 
amygdala immunoreactive per ikarya are more abundant [30]. 
Furthermore,  we have been unable to detect  dynorphin- 
positive structures in the monkey hippocampus, or dentate 
gyrus mossy fiber projections onto the pyramidal cells of 
areas CA2 and CA3 as reported in the rat brain [30,34]. 
However,  these latter observations have depended upon the 
use of neurotoxins such as kainic acid and colchicine in- 
jected directly into the hippocampus [34] or relatively high 
doses of colchicine administered intracerebroventricularly 
[30,35] in order to enhance immunoreactivity in neurons 
which may contain very low levels of stored peptide. By 
contrast,  the relatively low levels of colchicine used in the 
present study may have precluded the visualization of small 
quantities of peptide present in cortical and hippocampal 
areas. Nevertheless,  studies on the distribution of 
enkephalin in the hippocampus have also noted only scant or 
no immunoreactivity in either the monkey [17] or the human 
[1]. 
Despite these apparent species differences, some of 
which may be due to procedural variables as indicated 
above, there are also striking similarities between rat and 
monkey in the distribution of  prodynorphin peptide systems 
in brain. For  example,  two of the best defined dynorphin 
systems, the striato-nigral and magnocellular hypothalamic, 
appear to be present in both species, indicating the 
possibility of a similarity and thus conservation of proposed 
physiological functions of dynorphin, i.e., in extrapyramidal 
motor and neuroendocrine regulation, respectively. In addi- 
tion, dynorphin perikarya are present in both species in other 
hypothalamic nuclei (e.g., lateral hypothalamic area and ar- 
cuate or infundibular nucleus), and caudally in the 
periaqueductal gray (substantia grisea centralis), parabrac- 
hial nucleus, nucleus tractus solitarius, lateral reticular nu- 
cleus, and spinal trigeminal nucleus. The apparent conser- 
vation of dynorphin systems in these structures, which are 
important in consummatory and reproductive behavior, and 
organismic responses to pain and stress, suggests that 
prodynorphin peptides may have a significant physiological 
role in these fundamental processes,  mediated by actions at 
opioid and perhaps also non-opioid receptors [54,55]. The 
most marked species differences appear  to be in systems 
important for behavioral plasticity, e.g., cerebral cortex and 
hippocampus,  although such apparent differences must be 
regarded cautiously for technical reasons. Nevertheless,  it is 
possible that the extensive species differences in telence- 
phalic dynorphin systems reflect a divergence of some of the 
functional roles of prodynorphin peptides in these species. 
Such divergence is consistent with the finding of widespread 
differences in the distribution of opioid receptors in rat and 
rhesus monkey brain [32, 33, 56, 68]. Since there are also 
species and regional differences in the processing of 
prodynorphin [7,8], it is clear that more intensive studies of 
the individual dynorphin systems, especially in relation to 
the peptide forms and opioid receptor subtypes present, will 
be important to lay the groundwork for understanding the 
physiological functions of dynorphin in the brain. 
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